Format

Send to

Choose Destination
See comment in PubMed Commons below
BJU Int. 2012 Oct;110(8):1155. doi: 10.1111/j.1464-410X.2012.11061.x. Epub 2012 Feb 28.

Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center